MDMA-Assisted Psychotherapy for Borderline Personality Disorder

Introduction

Borderline personality disorder (BPD) is described as a severe and complex psychiatric condition with high rates of suicidality, substantial impairment in psychosocial functioning, and symptoms spanning behavioural, affective, interpersonal, and cognitive domains. Existing treatment options include specialist psychotherapies such as mentalization-based therapy (MBT) and dialectical behaviour therapy (DBT), which reduce self-harm and suicidal behaviour for many patients, but overall outcomes show large heterogeneity, high dropout (about 50% in one review), and persistent interpersonal and affective difficulties for a substantial subset. The authors highlight that interpersonal stressors, intolerance of aloneness, fears of abandonment and heightened negative affectivity are core features that remain insufficiently addressed by current interventions, contributing to ongoing suicide risk and long-term functional impairment. This paper sets out to evaluate the plausibility of researching 3,4-methylenedioxymethamphetamine-assisted psychotherapy (MDMA-AP) as a complementary treatment for BPD. Drawing on evidence for MDMA-AP in conditions with phenomenological and neurobiological overlap with BPD—especially post-traumatic stress disorder (PTSD)—the authors outline potential treatment targets and hypothesised mechanisms by which MDMA-AP might affect interpersonal, affective and identity disturbances in BPD. They conclude by offering initial considerations for clinical trial design to assess safety, feasibility and preliminary clinical effects in this population.